BAM
BPMC

Blueshift Asset Management’s Blueprint Medicines BPMC Stock Holding History

Blueshift Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,086
Closed -$273K – 460
2025
Q1 		$273K Buy
+3,086
New +$301K 0.11% 287
2024
Q4 		– Sell
-2,998
Closed -$277K – 380
2024
Q3 		$277K Buy
+2,998
New +$298K 0.07% 290
2021
Q1 		– Sell
-5,505
Closed -$617K – 863
2020
Q4 		$617K Buy
+5,505
New +$580K 0.07% 368

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Blueshift Asset Management's BPMC Position: Q2 2025 in Review

Blueshift Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3,086 shares — an estimated $273K sold.

Blueshift Asset Management first reported a position in BPMC in Q4 2020 and held it in 3 quarters. The position peaked at $617K in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Blueshift Asset Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Blueshift Asset Management sold 3,086 Blueprint Medicines shares in Q2 2025, an estimated $273K.
  • Blueshift Asset Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 3 quarters.
  • Blueshift Asset Management's Blueprint Medicines position peaked at $617K in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Blueshift Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.